CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Asgard Therapeutics is developing a novel cancer immunotherapy called TrojanDC, which reprograms cancer cells into antigen-presenting dendritic cells. This approach aims to enhance the immune system's ability to recognize and attack tumors, addressing the limitations of current immunotherapies.
The Challenge:
Cancer remains one of the major challenges to modern medicine affecting one-in-three people in Europe.
Available immunotherapies are effective in a limited number of patients and often lose their efficacy due to heterogeneity and lack of tumor-antigen presentation.
Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets.
Large players like Merck, Pfizer, and Novartis have shown to be keen on acquisitions of high-potential te…
ASGARD THERAPEUTICS AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
